346 related articles for article (PubMed ID: 28483516)
1. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
[TBL] [Abstract][Full Text] [Related]
2. Molecular changes in endometriosis-associated ovarian clear cell carcinoma.
Worley MJ; Liu S; Hua Y; Kwok JS; Samuel A; Hou L; Shoni M; Lu S; Sandberg EM; Keryan A; Wu D; Ng SK; Kuo WP; Parra-Herran CE; Tsui SK; Welch W; Crum C; Berkowitz RS; Ng SW
Eur J Cancer; 2015 Sep; 51(13):1831-42. PubMed ID: 26059197
[TBL] [Abstract][Full Text] [Related]
3. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
Wang Q; Wang L; L Y; Ding X; Liu A
J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
[TBL] [Abstract][Full Text] [Related]
4. Reactive oxygen species downregulate ARID1A expression via its promoter methylation during the pathogenesis of endometriosis.
Xie H; Chen P; Huang HW; Liu LP; Zhao F
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4509-4515. PubMed ID: 29131266
[TBL] [Abstract][Full Text] [Related]
5. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis.
Guo C; Ren F; Wang D; Li Y; Liu K; Liu S; Chen P
Oncol Rep; 2014 Dec; 32(6):2580-8. PubMed ID: 25333219
[TBL] [Abstract][Full Text] [Related]
6. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
7. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
8. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
Borrelli GM; Abrão MS; Taube ET; Darb-Esfahani S; Köhler C; Chiantera V; Mechsner S
Mol Hum Reprod; 2016 May; 22(5):329-37. PubMed ID: 26832958
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
10. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
11. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
12. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
13. ARID1A, Prostaglandin E2, and Its Receptor as Possible Predictors of Malignant Transformation of the Endometrium in Endometriosis.
Dyatlova AS; Lin'kova NS; Polyakova VO; Samoshkin NG; Kvetnoi IM
Bull Exp Biol Med; 2019 Aug; 167(4):504-507. PubMed ID: 31494765
[TBL] [Abstract][Full Text] [Related]
14. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
15. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
[TBL] [Abstract][Full Text] [Related]
16. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
[TBL] [Abstract][Full Text] [Related]
17. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing the progression of an endometrioma: Benign or malignant?
Bastu E; Onder S; Demiral I; Ozsurmeli M; Keskin G; Takmaz O; Ozaltin S; Gorgen H; Gungor M; Yavuz E; Buyru F
Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():79-84. PubMed ID: 30245441
[TBL] [Abstract][Full Text] [Related]
19. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Wilson MR; Reske JJ; Holladay J; Wilber GE; Rhodes M; Koeman J; Adams M; Johnson B; Su RW; Joshi NR; Patterson AL; Shen H; Leach RE; Teixeira JM; Fazleabas AT; Chandler RL
Nat Commun; 2019 Aug; 10(1):3554. PubMed ID: 31391455
[TBL] [Abstract][Full Text] [Related]
20. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis.
Li ZY; Zhu SS; Chen XJ; Zhu J; Chen Q; Zhang YQ; Zhang CL; Guo TT; Zhang LM
Biochem Biophys Res Commun; 2017 Nov; 493(2):1018-1025. PubMed ID: 28942143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
